• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Heart J Case Rep . Effusive-constrictive pericarditis after the second dose of BNT162b2 vaccine (Comirnaty): a case report

tetano

Editor, Senior Moderator
Eur Heart J Case Rep


. 2022 Jan 12;6(2):ytac012.
doi: 10.1093/ehjcr/ytac012. eCollection 2022 Feb.
Effusive-constrictive pericarditis after the second dose of BNT162b2 vaccine (Comirnaty): a case report


Giacomo Maria Viani[SUP] 1 [/SUP], Patrizia Pedrotti[SUP] 2 [/SUP], Romano Seregni[SUP] 1 [/SUP], Brucato Antonio[SUP] 3 [/SUP]



Affiliations

Abstract

Background: Whereas effusive-constrictive pericarditis (ECP) can rarely occur in coronavirus disease 2019 (COVID-19), to date no cases of ECP related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine have been documented.
Case summary: A 59-year-old Caucasian man presented to our emergency department with ECP. Symptoms occurred shortly after the second dose of BNT162b2 (Comirnaty) vaccine. No other aetiological causes were identified. Guidelines-directed therapy for acute pericarditis was implemented, with clinical benefit.
Discussion: Systemic inflammatory response to COVID-19 can rarely trigger pericarditis. In our case, a strong temporal relationship between the second dose of BNT162b2 vaccine and symptoms occurrence was documented, indicating a possible rare adverse reaction to the vaccine, similarly to natural infection. Further research is needed to confirm a causal relationship.

Keywords: BNT162b2; COVID-19; Case report; Effusive–constrictive pericarditis; SARS-CoV2; Vaccine.
 
Back
Top Bottom